Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany.
Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis.
Anti-CD20 inhibits T cell-mediated pathology and microgliosis in the rat brain.
Multiple sclerosis: Oral BG12 for treatment of relapsing-remitting MS.
New methods for multiple sclerosis drug discovery.
One of the oldest patients with Neuromyelitis Optica in the literature.
Enigmatic GPCR Finds a Stimulating Drug.
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.
The role of MRI in the evaluation of secondary progressive multiple sclerosis.
Immune Therapy of Multiple Sclerosis - Future Strategies.
Looking anew at cognitive dysfunction in multiple sclerosis: The gorilla in the room.
Transcriptional targeting of DCs with lentiviral vectors induces antigen-specific tolerance in a mouse model of multiple sclerosis.
Words: Perception, "-Omics" Another Epidemic? Vaccine Optic Neuritis; An Amblyopia Symposium; Strasbismus surgery anesthesia.
A Potent and Selective S1P(1) Antagonist with Efficacy in Experimental Autoimmune Encephalomyelitis.
Acquired channelopathies as contributors to development and progression of multiple sclerosis.
Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
New Microparticle Secondary Progressive MS Therapy Dosing Tested In Australian Clinical Trial
Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis.
Multiple rodent models and behavioral measures reveal unexpected responses to FTY720 and DMF in experimental autoimmune encephalomyelitis.
Simvastatin inhibits secretion of Th17-polarizing cytokines and antigen presentation by DCs in patients with relapsing remitting multiple sclerosis.
Neuroinflammatory Imaging Biomarkers: Relevance to Multiple Sclerosis and its Therapy.
In vitro and in vivo evaluation of a humanized anti-APRIL antibody.
Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia.
Interleukin 18 gene polymorphism is a risk factor for multiple sclerosis.
Autoantigen conformation influences both B- and T-cell responses and encephalitogenicity.

Pages